YourLawyer.com® 1-800-LAW-INFO (1-800-529-4636)

Parker Waichman Alonso LLP Headlines by Topic

Tysabri

CORRECTION: MULTIPLE SCLEROSIS DRUG (TYSABRI) MAY HAVE BEEN RESPONSIBLE FOR FOURTH CASE OF RARE BRAIN DISEASE

Jun 4, 2005 | www.Newsinferno.com
Yesterday, we reported that the FDA had been informed by Biogen Idec Inc. that a fourth person may have died from a rare and often fatal brain...

MULTIPLE SCLEROSIS DRUG (TYSABRI) MAY HAVE BEEN RESPONSIBLE FOR FOURTH DEATH FROM RARE BRAIN DISEASE

Jun 3, 2005 | www.Newsinferno.com
The FDA has been informed by Biogen Idec Inc. that a fourth person may now have died from a rare brain disease known as progressive multifocal...

Warning Didn't Slow Approval of MS Drug

Mar 2, 2005 | Los Angeles Times
A multiple sclerosis drug pulled off the market after a patient died was approved by the Food and Drug Administration even though a prominent...

Makers Take MS Drug Tysabri Off Market After Death

Mar 1, 2005 | AP
The makers of Tysabri, a new drug used to treat multiple sclerosis, said yesterday that they are voluntarily suspending sales of the drug because one...

Biogen, Elan Voluntarily Withdraw Tysabri

Feb 28, 2005 | AP
Biogen Idec Inc. and Elan Corp. announced Monday they have voluntarily withdrawn a recently approved drug used to treat multiple sclerosis after one...

Biogen, Elan Halt MS Drug After Patient Death

Feb 28, 2005 | AP
Biogen Idec (BIIB) and Elan Corp. Plc (ELN) on Monday suspended sales of their much-heralded new multiple sclerosis drug after a patient died from a...

BIOGEN IDEC AND ELAN ANNOUNCE VOLUNTARY SUSPENSION OF TYSABRI

Feb 28, 2005 | www.biogen.com
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today a voluntary suspension in the marketing of TYSABRI® (natalizumab), a...

Suspended Marketing of Tysabri (natalizumab)

Feb 28, 2005 | www.fda.gov
FDA is issuing this public health advisory to inform patients and health care providers about the suspended marketing of Tysabri (natalizumab) due to...

FDA Issues Public Health Advisory on Tysabri, a New Drug for MS

Feb 28, 2005 | www.fda.gov
The Food and Drug Administration (FDA) today issued a public health advisory to inform patients and health care providers about the suspended...

Page 4/4 [first] [prev] 1 2 3 4 [next] [last]

Tysabri
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

Date you started taking the drug (mm-yyyy):

Date you stopped taking the drug (mm-yyyy):

Please describe any side effects:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Home | Defective Drugs | Medical Devices | Toxic Substances | Accidents | Product Liability | Malpractice | Diseases
Nursing Home Negligence | Food Poisoning | Other Topics | Social Security Disability | Contact
Statement of Clients' Rights | Site Map | Drug Injury Search | Vioxx | Mesothelioma | Permax | Dostinex | Composix Kugel Mesh X Large Patch
Ortho Evra | Fosamax | Personal Injury Lawyer | Fusarium Keratitis | Stevens Johnson Syndrome | Florida Personal Injury Law Firm

© 2002-2009 YourLawyer.com®. All Rights Reserved.

Please note that you are not considered a client until you have signed a retainer agreement and your case has been accepted by us.
Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Attorney Advertising

Parker Waichman Personal Injury News